SCHEMBL337927

SCHEMBL337927

CC(C)(C)OC(=O)NCc1cc2ncc(C(=O)O)n2cc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 2/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 1/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MAPK8 P45983 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338980 0.90 IDO1 (0.39) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL339005 0.88 IDO1 (0.40) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL338256 0.88 IDO1 (0.40) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL339213 0.83 IDO1 (0.38) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL339781 0.83 ALDH1A1 (0.38) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL339323 0.83 ALDH1A1 (0.38) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL1913166 0.82 MARS1 (0.40) MEN1KMT2ANPC1POLB
SCHEMBL339441 0.81 IDO1 (0.41) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL337909 0.80 IDO1 (0.41) IDO1ALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL868834 0.79 DPP4 (0.39) NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
EP-2004643-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077787-A1 ORGANIC COMPOUNDS OAT, GPR119, OTC IDO1 1621/4885ALDH1A1 480/4885SMN1; SMN2 1926/4885
US-20090253689-A1 Organic Compounds OAT, GPR119, OTC IDO1 1621/4885ALDH1A1 480/4885SMN1; SMN2 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.